Thanks for highlighting that! The significance of the data being proprietary suggests that not only is it a likely derivative of a patent pending but also that PTX is really honing in on solid tumors as the space to crack wide open! Your banging on (as you described it not me ) about our most recent patent application (Universal Receptor Immune Cell Therapy) and PTX-200 is an AKT-inhibitor.along with CellPryme A and M appears to have a lot to do with application in the solid turmor space.... where the most monetary and patient benefit will be derived.
Guess this sort of R&D is part and parcel of risk-mitigation and identifying one's market for best ROI.... starting to feel like we could be getting to the pointy end of some newsflow too.
) about our most recent patent application (Universal Receptor Immune Cell Therapy) and PTX-200 is an AKT-inhibitor.along with CellPryme A and M appears to have a lot to do with application in the solid turmor space.... where the most monetary and patient benefit will be derived.
